The Latest Breaking News from CVS Health

As inflation shows signs of easing and the Fed is expected to slow the pace of rate hikes, the market’s prospects look bright. Therefore, fundamentally strong stocks CVS Health (CVS), Archer-Daniels-Midland (ADM), and Box (BOX) could keep soaring. Wall Street analysts expect upsides in these stocks over the next 12…

With the Fed indicating that the pace of rate hikes might slow down, growth stocks could see a rebound. Therefore, it could be wise to buy CVS Health (CVS), Archer-Daniels-Midland (ADM), The Mosaic Company (MOS), and MaxLinear (MXL), which possess solid growth attributes. Keep reading….

The retail giant becomes the latest major player in the drug industry to announce a plan to settle lawsuits filed by state and local governments over the toll of opioids sold at its pharmacies.

The healthcare industry tends to withstand macroeconomic pressure better than other industries due to the almost inelastic demand for medical products and services. With a recession expected next year, investors could look to capitalize on the defensive characteristics and long-term prospects of the industry by investing in quality medical stocks…

The two largest US pharmacy chains, CVS Health and Walgreen Co., announced agreements in principle on Wednesday to pay about $5 billion each to settle lawsuits nationwide over the toll of opioids, and a lawyer said Walmart, a third pharmacy behemoth, is in discussions for a deal.

Someone with a lot of money to spend has taken a bearish stance on CVS Health (NYSE:CVS). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

It could amount to the last round of huge settlements after years of litigation over the industry's role in an overdose crisis linked to more than 500,000 deaths in the U.S. over the past two decades.

Reuters

CVS Health says it has agreed to pay about $5 billion to state, local and Native American tribal governments to settle lawsuits over the toll of opioids

Someone with a lot of money to spend has taken a bullish stance on CVS Health (NYSE:CVS). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

‘We’ve reduced the price on CVS Health brand period products by 25 per cent in core CVS Pharmacy locations,’ the pharmacy said in a satement